JPMorgan Upgrades Acadia Pharmaceuticals (ACAD) to Overweight, 'we see limited downside in the stock at current level'
Tweet Send to a Friend
(Updated - October 10, 2023 7:45 AM EDT)
JPMorgan analyst Tessa Romero upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
